JP2016199583A5 - - Google Patents

Download PDF

Info

Publication number
JP2016199583A5
JP2016199583A5 JP2016152696A JP2016152696A JP2016199583A5 JP 2016199583 A5 JP2016199583 A5 JP 2016199583A5 JP 2016152696 A JP2016152696 A JP 2016152696A JP 2016152696 A JP2016152696 A JP 2016152696A JP 2016199583 A5 JP2016199583 A5 JP 2016199583A5
Authority
JP
Japan
Prior art keywords
dota
complex
scn
reaction mixture
radioactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016152696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016199583A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016199583A publication Critical patent/JP2016199583A/ja
Publication of JP2016199583A5 publication Critical patent/JP2016199583A5/ja
Pending legal-status Critical Current

Links

JP2016152696A 2009-07-22 2016-08-03 放射性免疫複合体を生成するための方法 Pending JP2016199583A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22771009P 2009-07-22 2009-07-22
US61/227,710 2009-07-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012521780A Division JP5985392B2 (ja) 2009-07-22 2010-07-22 放射性免疫複合体を生成するための方法

Publications (2)

Publication Number Publication Date
JP2016199583A JP2016199583A (ja) 2016-12-01
JP2016199583A5 true JP2016199583A5 (https=) 2017-01-26

Family

ID=43499411

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012521780A Active JP5985392B2 (ja) 2009-07-22 2010-07-22 放射性免疫複合体を生成するための方法
JP2016152696A Pending JP2016199583A (ja) 2009-07-22 2016-08-03 放射性免疫複合体を生成するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012521780A Active JP5985392B2 (ja) 2009-07-22 2010-07-22 放射性免疫複合体を生成するための方法

Country Status (8)

Country Link
US (1) US9603954B2 (https=)
EP (1) EP2456472B1 (https=)
JP (2) JP5985392B2 (https=)
CN (2) CN104710504B (https=)
CA (1) CA2768658C (https=)
IN (1) IN2012DN00551A (https=)
RU (2) RU2704802C2 (https=)
WO (1) WO2011011592A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes
US20150157742A1 (en) * 2013-12-11 2015-06-11 The European Atomic Energy Community (Euratom), Represented By The European Commission SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225
CA2949365A1 (en) * 2014-05-16 2015-11-19 Memorial Sloan Kettering Cancer Center One-step labeling of antibodies to high specific activity with actinium-225
CN108348604B (zh) * 2015-09-08 2022-04-29 沃特世科技公司 用于分析抗体-药物缀合物的多维色谱方法
US11896683B2 (en) 2016-12-16 2024-02-13 The Australian National University Radiolabelled material for targeted administration
DK3568205T3 (da) 2017-01-12 2023-10-09 Radiomedix Inc Behandling af cancerceller, der overeksprimerer somatostatinreceptorer ved at anvende radioisotop-chelaterede ocreotid-derivater
EP3661557B1 (en) * 2017-07-31 2025-09-03 Actinium Pharmaceuticals, Inc. Treatments for a hematological malignancy
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
WO2022056354A1 (en) * 2020-09-11 2022-03-17 Actinium Pharmaceuticals, Inc. Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
US12447218B1 (en) * 2021-02-09 2025-10-21 Actinium Pharmaceuticals, Inc. Radioconjugates directed to MHC-complexed antigens in cancer
US20250339571A1 (en) * 2021-08-27 2025-11-06 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer
WO2023183927A2 (en) 2022-03-24 2023-09-28 Actinium Pharmaceuticals, Inc. Humanized anti-cd45 antibodies
US20250177583A1 (en) 2022-03-30 2025-06-05 Nihon Medi-Physics Co., Ltd. Method for producing complex
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
AU2023330110A1 (en) 2022-08-22 2025-03-06 Abdera Therapeutics Inc. Dll3 binding molecules and uses thereof
US20250388688A1 (en) 2024-04-04 2025-12-25 Ethyreal Bio, Inc. Anti-tshr antibodies and uses thereof
US12600794B2 (en) 2024-07-23 2026-04-14 Abdera Therapeutics Inc. 5T4 binding polypeptides and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001387A (en) 1973-07-30 1977-01-04 Medi-Physics, Inc. Process for preparing radiopharmaceuticals
US4305922A (en) 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4296785A (en) 1979-07-09 1981-10-27 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4732864A (en) 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4894364A (en) 1983-10-26 1990-01-16 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4663129A (en) 1985-01-30 1987-05-05 The United States Of America As Represented By The United States Department Of Energy Isotopic generator for bismuth-212 and lead-212 from radium
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5306509A (en) 1987-03-17 1994-04-26 Turner Robert E Prevention and treatment of oral lesions
AU2068588A (en) 1987-08-12 1989-02-16 Immunomedics Inc. Preparation of radiolabeled conjugates
US4833329A (en) 1987-11-20 1989-05-23 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US5612016A (en) * 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
AU630362B2 (en) 1988-05-25 1992-10-29 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Macrocyclic chelates & methods of use thereof
US4923985A (en) 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
US5292868A (en) 1989-05-26 1994-03-08 Akzo N.V. Chelating agents for attaching metal ions to proteins
DE69007430T2 (de) 1989-06-19 1994-07-07 Akzo Nobel N.V., Arnheim/Arnhem Radioimmuntherapie unter alphapartikelausstrahlung.
CA2063551C (en) 1989-07-12 2000-05-16 Jacobus D.M. Herscheid Method for preparing radiodiagnostic gaseous radionuclide and apparatus
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
LU87684A1 (de) 1990-02-23 1991-10-08 Euratom Verfahren zur erzeugung von aktinium-225 und wismut-213
US5038046A (en) 1990-07-10 1991-08-06 Biotechnetics Method and generator for producing radioactive lead-212
US6403771B1 (en) 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
CA2100709C (en) 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US6458933B1 (en) 1998-05-20 2002-10-01 Immunomedics, Inc. Therapeutic using a bispecific antibody
ES2299256T3 (es) 1998-05-26 2008-05-16 Sloan-Kettering Institute For Cancer Research Constructos que emiten particulas alfa y sus usos.
WO1999066951A2 (en) 1998-06-22 1999-12-29 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
AU2002211232B2 (en) 2000-09-15 2006-10-19 Sloan Kettering Institute For Cancer Research Targeted alpha particle therapy using actinium-225 conjugates
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
US20040136908A1 (en) 2001-04-09 2004-07-15 Olson William C. Anti-cd19 immunotoxins
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
AU2003210149B2 (en) 2002-01-03 2008-10-09 Bayer Schering Pharma Aktiengesellschaft Conjugates comprising an antibody specific for the ED-B domain of fibronectin and their use for the detection and treatment of tumours
US20040022726A1 (en) 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
US20060058218A1 (en) 2004-09-10 2006-03-16 General Electric Company Solid phase conjugation of complexing agents and targeting moieties
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
EP2015775B1 (en) 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody

Similar Documents

Publication Publication Date Title
JP2016199583A5 (https=)
JP2025100545A (ja) 鉛またはトリウム放射性核種に連結されたpsma標的化化合物を含む錯体
JP2020518674A5 (https=)
CN109310789B (zh) 制备212Pb标记的单克隆抗体
AU2019435951B2 (en) Chelators and methods of making and using same
AU2015258801B2 (en) One-step labeling of antibodies to high specific activity with actinium-225
EP2497501B1 (en) Radionuclides for medical use
Paterson et al. Bifunctional 64 Cu-labelled macrobicyclic cage amine isothiocyanates for immuno-positron emission tomography
CN117836011A (zh) 将生物制剂与多种螯合剂组合的方法和材料
CN114555132A (zh) 放射性金属标记抗体的制造方法
JP2023076712A (ja) 放射標識生体分子およびその使用
TW202325343A (zh) 去醣基化抗體之放射性複合體,及放射性醫藥
NO178571B (no) Analogifremgangsmåte for fremstilling av et bifunksjonelt chelateringsmiddel
WO2024090488A1 (ja) 放射性医薬組成物
WO2023183944A2 (en) Her3 nanobodies
JP6514712B2 (ja) ピコリン酸架橋シクラム、金属カチオンとのキレートおよびそれらの使用
AU698763B2 (en) Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
JPH05502219A (ja) 安定な治療用放射性核種およびそれを調製する方法
EP0662842A1 (en) Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
WO2022224980A1 (ja) 抗cd20抗体の放射性複合体、及び、放射性医薬
WO2025030160A1 (en) Chelating compounds and methods of uses thereof
CA2199387A1 (en) Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
WO2023157822A1 (ja) 抗vegf抗体の放射性複合体、及び、放射性医薬
KR101239130B1 (ko) Mri 조영제 및 그 제조방법
CN121041473A (zh) 一种双功能性融合蛋白、放射性核素标记物及其应用